Press Release

Health2047 Expands Advisory Board with New Strategic Appointments

Accomplished business leaders and technologists bring years of experience to guide system-level healthcare transformation

MENLO PARK, Calif., July 31, 2019 —

Health2047 Inc., a Silicon Valley business formation and commercialization enterprise launched by the American Medical Association (AMA), today announced the appointment of industry experts Charles Hoyng, Jay Kaminski, Georgia Papathomas and Craig Taylor to its advisory board. These four industry veterans will lend their business, technology, and investment acumen to support the Health2047 team develop and launch powerful new businesses to transform the $3.4 trillion U.S. healthcare industry.

Health2047 Inc. and its strategic partners catalyze system-level solutions in four areas: data, chronic care, radical productivity and healthcare value. The company’s first spin out, Akiri, is building a cloud-based, peer-to-peer network to enable trusted data exchange across the complex U.S. healthcare economy. Health2047’s most recent spinout, First Mile Care, is a preventive chronic care company that is building an affordable, scalable and sustainable platform to reverse prediabetes.

“In order to tackle healthcare’s biggest challenges, our expanding team collaborates closely with both the physician community and technology leaders,” said Health2047 Chief Executive Officer Lawrence K. Cohen. “Charles, Jay, Georgia and Craig are revered industry experts whose vast knowledge and experience will undoubtedly help Health2047 expedite meaningful market innovations and impact.”

The new members joining Health2047:

– Charles Hoyng – Hoyng brings over 30 years of experience in counseling the development, protection, manufacture and distribution of pharmaceutical and medical diagnostic products. In between receiving his Ph.D. in Organic Chemistry from MIT and his law degree from the University of California, Berkeley, Hoyng was a post-doctoral research fellow at the California Institute of Technology, a member of the faculty in the department of chemistry at Texas A&M University, and held several positions at Genentech including Science Director, Organic Chemistry, and Project Team Leader of Genentech’s recombinant tissue plasminogen activator (rtPA) project leading to FDA approval of Activase® (alteplase).

– Jay Kaminski – Kaminski is currently Chief Operating Officer at Celularity. Previously, he spent 20 years at Celgene Corporation where he served as SVP, Global Clinical Research & Development Operations. Kaminski brings nearly 30 years of experience in the pharmaceutical and biotechnology industry covering a broad range of therapeutic areas. He received his B.S. in Business Management from Ithaca College.

– Georgia Papathomas – Papathomas is an active investor, advisor and board member with over 40 years of experience in life sciences, telecommunications, and technology. She retired from Johnson & Johnson as the Senior Vice President and Global Head of Data Sciences. Previously she was the CIO and a member of the Group Operating Committee (GOC) of Johnson & Johnson Pharmaceuticals. She started her career at Bell Labs in basic research. Papathomas received her Ph.D. and M.S. in Engineering Science and her B.S. in Civil Engineering all from Columbia University.

– Craig Taylor ­– Taylor is the Co-founder and Head of Life Science Investments at Alloy Ventures. His career in venture capital began in 1977, and since co-founding Alloy Ventures in 1996, he and his partners have invested in over 100 companies. In the last decade, Taylor has focused on investing in life science companies that span research tools, diagnostics, pharmaceuticals and medical devices. Taylor holds a B.A. and M.A. in Physics from Brown University and an M.B.A. from Stanford University.

The new advisors will join existing advisory board members Steve Bochner, Joe Marks, Karl Ronn, Allison Spinner, Walter Stewart, Christine Stock, Norman Winarsky and Stephen Wong, to compliment the extensive leadership and expertise provided to Health2047 by the AMA. “We are extraordinarily proud and honored to have such an accomplished group of healthcare technology leaders on our advisory board,” said Cohen. “With decades of experience in medicine, AI, machine learning, market adoption strategies, IT management, venture investing, and public health, our executives and advisors are committed to launching solutions that will shape the next-generation of healthcare.”

About Health2047
Health2047 Inc. is a Silicon Valley business formation and commercialization enterprise committed to catalyzing fundamental transformation in U.S. healthcare. The company’s specific areas of focus include data liquidity, chronic care prevention, radical productivity enhancement, and value-based payment. Health2047’s deep relationships with both the American Medical Association and its network of strategic partners create a unique force multiplier that helps drive large-scale changes in healthcare. For more information, please visit http://health2047.com.